120 Participants NeededMy employer runs this trial

Fianlimab + Cemiplimab for Head and Neck Cancer

Recruiting at 9 trial locations
CT
Overseen ByClinical Trials Administrator
Age: 18+
Sex: Any
Trial Phase: Phase 2
Sponsor: Regeneron Pharmaceuticals
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain any real medicine), collectively called "study drugs" in this form.

The study is focused on participants with head and neck cancers who have not been previously treated for head and neck cancer that has come back or spread to other parts of the body, referred to as recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

The study is looking at several other research questions, including:

* What side effects may happen from taking the study drugs

* How much of each study drug is in the blood at different times

* Whether the body makes antibodies against the study drug(s) individually (which could make the study drugs less effective or could lead to side effects)

* Compatible research to better understand the study drugs and HNSCC

Who Is on the Research Team?

CT

Clinical Trial Management

Principal Investigator

Regeneron Pharmaceuticals

Are You a Good Fit for This Trial?

Inclusion Criteria

I have at least one tumor that can be measured on scans.
I am fully active or have only minor physical limitations.
I have head and neck cancer that cannot be cured with local treatments.
See 4 more

What Are the Treatments Tested in This Trial?

Interventions

  • Cemiplimab
  • Fianlimab

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Group I: Cohort 2Experimental Treatment3 Interventions
Group II: Cohort 1Experimental Treatment3 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Regeneron Pharmaceuticals

Lead Sponsor

Trials
690
Recruited
948,000+
Founded
1988
Headquarters
Tarrytown, USA
Known For
Precision medicine
Top Products
Dupixent, EYLEA, Libtayo, Praluent
Leonard Schleifer profile image

Leonard Schleifer

Regeneron Pharmaceuticals

Chief Executive Officer since 1988

MD and PhD in Medicine

George Yancopoulos profile image

George Yancopoulos

Regeneron Pharmaceuticals

Chief Medical Officer since 1997

MD from Harvard Medical School